EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hotspot issues and considerations in multi-gene testing in breast cancer

Nanlin Li, Guangyu Liu, Anqin Zhang, Xiaoan Liu, Hong Hu, Hengyu Li, Dan Zhou, Cheng Wang, Shou-Ching Tang, Hong Liu

Holistic Integrative Oncology · 02.11.2026 · 5 (1)

DOI: 10.1007/s44178-026-00288-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Holistic Integrative Oncology, online erschienen am 02.11.2026. Verfasst von Nanlin Li und 9 weiteren Autor:innen. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multigene testing serves as a cornerstone of precision oncology, reshaping the holistic management of breast cancer across its continuum. In early-stage HR-positive/HER2-negative (HR+/HER2-) disease, genomic assays such as MammaPrint ® and Oncotype DX ® enable refined risk stratification; however, their evidence bases diverge significantly when extrapolated to node-positive (1–3 LN+) populations, where only MammaPrint ® currently meets the threshold for guiding chemotherapy de-escalation. For premenopausal patients, age acts as an effect modifier, necessitating the integration of genomic risk with clinical and ovarian function suppression considerations. Beyond adjuvant decisions, these assays also inform extended endocrine therapy duration and anthracycline-sparing strategies, albeit with varying levels of evidence. In advanced disease, dynamic monitoring of resistance driver genes—particularly ESR1 and PIK3CA via circulating tumor DNA (ctDNA)—is critical for overcoming endocrine resistance and tailoring targeted therapies. Notably, ctDNA analysis facilitates the detection of “molecular recurrence” prior to radiological progression, shifting surveillance toward preemptive intervention. Liquid biopsy further provides risk stratification and treatment response evaluation in both early and advanced settings. Despite persistent challenges regarding cross-platform discordance and standardization, multigene testing epitomizes the integration of molecular insights with clinical practice. Ongoing research and health-economic evaluations, particularly within the Chinese healthcare context, promise to refine these strategies toward truly individualized care.

Zitieren

APA

Li, N., Liu, G., Zhang, A., Liu, X., Hu, H., Li, H., Zhou, D., Wang, C., Tang, S., & Liu, H. (2026). Hotspot issues and considerations in multi-gene testing in breast cancer. Holistic Integrative Oncology, 5(1). https://doi.org/10.1007/s44178-026-00288-3

Vancouver

Li N, Liu G, Zhang A, Liu X, Hu H, Li H, et al. Hotspot issues and considerations in multi-gene testing in breast cancer. Holistic Integrative Oncology. 2026;5(1). doi:10.1007/s44178-026-00288-3

BibTeX
@article{Li2026,
  author = {Li, Nanlin and Liu, Guangyu and Zhang, Anqin and Liu, Xiaoan and Hu, Hong and Li, Hengyu and Zhou, Dan and Wang, Cheng and Tang, Shou-Ching and Liu, Hong},
  title = {Hotspot issues and considerations in multi-gene testing in breast cancer},
  journal = {Holistic Integrative Oncology},
  year = {2026},
  volume = {5},
  number = {1},
  doi = {10.1007/s44178-026-00288-3}
}
Kostenlos starten →